3rd Quarter - Report

TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Economics/Economic Development ECN

All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2052 (113th)

Animals ANI

Education and awareness regarding illegal compounding of veterinary drugs for animals.

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Extension of the U.S. R&D tax credit. Issues related to Corporate Tax Reform. Provisions of H.R.2535 and S.1647 "Restoring Access to Medication Act of 2013." HR 4718 " To Amend the Internal Revenue Code of 1986 to Modify and Make Permanent Bonus Depreciation". HR 3474 "Hire more Heroes Act of 2014."

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1647 (113th), H.R. 4718 (113th), H.R. 2535 (113th), H.R. 3474 (113th)

Pharmacy PHA

General issues related to the 340B Federal Drug Pricing Program

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014."General issues related to the 21st Century Cures Initiative.

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2985 (113th), H.R. 4502 (113th)

Medicare/Medicaid MMM

Issues related to the Medicaid drug rebate policy; issues related to the Medicare Part B reimbursement of prescription drugs; and issues related to Medication Therapy Management.

Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.